‘Deals and a race to the bottom’: A glance at the weed industry on 4/20

Washington cannabis sales fell to about $1.14 billion in 2025 from roughly $1.47 billion in 2021, reflecting weaker demand and a price war across the dispensary market. Retailers in Spokane say large chains and new entrants are forcing 40% discounts and cheaper product mixes, pressuring smaller shops and rural dispensaries. The article is primarily a snapshot of industry softness and intensifying competition rather than a company-specific catalyst.

Analysis

The key market signal here is not brand degradation; it is category commoditization. When retail behaves like grocery and the shelf becomes interchangeable, the economic moat shifts away from the consumer-facing storefront and toward the lowest-cost capital, lowest-cost cultivation, and best purchasing leverage. That means large multi-store operators and vertically integrated players can keep taking share even as total category revenue drifts lower, while smaller independent dispensaries face a slow margin squeeze rather than an immediate demand shock.

The second-order effect is that wholesale pricing pressure will propagate backward through the supply chain. Farms with weak genetics, indoor power inefficiency, or high debt loads will likely be forced into consolidation, distressed asset sales, or white-label production for the bigger chains; the winners are the operators with scale to dictate terms and the cash flow to survive promo-driven traffic. This is also a regulation-sensitive setup: if state enforcement tightens around illicit supply or if interstate normalization ever improves, the pressure could ease, but that is a multi-year rather than quarter-level catalyst.

The biggest near-term risk is consumer fatigue plus wallet-share competition from alcohol, nicotine alternatives, and “cheap legal highs” competing on convenience and price. The article hints at a generational shift, which matters because the industry’s pricing power depends on repeat use, not one-off novelty purchases. If disposable income weakens again, volume may hold better than average selling price, but that still leaves EBITDA under pressure for retailers with fixed rent and labor costs.

The contrarian view is that the market may be overestimating how bad “race to the bottom” is for the sector winners. In a commoditizing consumer market, the lowest-cost operators often emerge stronger after a shakeout; this is a classic share-consolidation setup where headline revenue softness hides long-term operating leverage for the top few chains. The underappreciated trade is not broad cannabis beta, but dispersion: long the consolidators, short the vulnerable independents and high-cost cultivators.

Key Decisions for Investors

• Long CURLF / GTBIF on a 3-6 month horizon: both are better positioned to harvest share in a price-war environment due to scale and retail footprint; target 15-25% upside if promotional intensity persists, with a tighter stop if category pricing stabilizes.
• Short high-cost cannabis operators or levered cultivators versus a basket of large MSOs for 1-2 quarters: focus on names with weak gross margin and refinancing risk; this is a margin-compression trade, not a volume-collapse trade.
• Pair trade: long the largest multi-state operators, short regional dispensary exposure proxies where available; expect the spread to widen as smaller stores are forced into matching promos and losing traffic.
• If options are available, buy 6-9 month calls on the strongest cash-generating MSOs on weakness after sector drawdowns; the payoff comes from post-shakeout consolidation, not from near-term sales growth.
• Avoid buying broad cannabis beta on 4/20 hype; fade any one-day retail-driven pop unless there is fresh regulatory catalyst, because the better entry is after promo-driven margin commentary resets expectations.